Using Tissue Cell Culture To Make A Protein Or Polypeptide Patents (Class 435/70.1)
  • Patent number: 8053233
    Abstract: A novel polypeptide that functions as an IL-18 receptor is disclosed. The receptor is multimeric and includes at least one AcPL polypeptide, or fragment thereof, and at least one IL-1Rrp1 polypeptide, or fraction thereof. The receptor binds IL-18 and finds use in inhibiting biological activities mediated by IL-18.
    Type: Grant
    Filed: March 3, 2010
    Date of Patent: November 8, 2011
    Assignee: Immunex Corporation
    Inventors: John E. Sims, Teresa L. Born
  • Publication number: 20110262706
    Abstract: The present invention relates to an implant comprising: a sheet of bacterial cellulose having a macro-pattern positioned on at least a portion thereof. The invention also relates to a method for making such an implant.
    Type: Application
    Filed: November 6, 2009
    Publication date: October 27, 2011
    Applicant: SOFRADIM PRODUCTION
    Inventors: Yves Bayon, Sebastien Ladet, Olivier Lefranc, Philippe Gravagna
  • Patent number: 8044266
    Abstract: Compositions and methods for conferring pesticidal activity to bacteria, plants, plant cells, tissues and seeds are provided. Compositions comprising a coding sequence for a delta-endotoxin and delta-endotoxin-associated polypeptides are provided. The coding sequences can be used in DNA constructs or expression cassettes for transformation and expression in plants and bacteria. Compositions also comprise transformed bacteria, plants, plant cells, tissues, and seeds. In particular, isolated delta-endotoxin and delta-endotoxin-associated nucleic acid molecules are provided. Additionally, amino acid sequences corresponding to the polynucleotides are encompassed. In particular, the present invention provides for isolated nucleic acid molecules comprising nucleotide sequences encoding the amino acid sequences shown in SEQ ID NOS:3, 5, and 7, and the nucleotide sequences set forth in SEQ ID NO:1, 2, 4, and 6, as well as variants and fragments thereof.
    Type: Grant
    Filed: February 5, 2008
    Date of Patent: October 25, 2011
    Assignee: Athenix Corp.
    Inventors: Nadine Carozzi, Tracy Hargiss, Michael G. Koziel, Nicholas B. Duck, Brian Carr
  • Patent number: 8029778
    Abstract: A novel adaptor protein and its gene are provided. The novel adaptor protein has a property of binding to mammalian Toll-like receptor 3, which controls type I interferon production that is effective for prevention/treatment of viral infectious disease such as hepatitis B, hepatitis C, and the like, treatment of tumors, and the other purposes. Novel adaptor protein TICAM-1, which has an amino acid sequence set forth in SEQ ID NO: 2 or 4, specifically binds to the mammalian Toll-like receptor 3 and induces production of type I interferon. A mutant of the adaptor protein TICAM-1 has similar properties, provided that it has TIR domain (an amino acid sequence ranging from 394-position to 532-position in the amino acid sequence set forth in SEQ ID NO: 2 or an amino acid sequence ranging 396-position to 534-position in the amino acid sequence set forth in SEQ ID NO: 4). The gene is a gene encoding the adaptor protein TICAM-1.
    Type: Grant
    Filed: March 31, 2009
    Date of Patent: October 4, 2011
    Assignee: Japan Science and Technology Agency
    Inventors: Tsukasa Seya, Misako Matsumoto, Hiroyuki Oshiumi
  • Patent number: 8030026
    Abstract: The subject invention relates to antibodies to troponin I as well as methods of use thereof. In particular, such antibodies may be used to detect Troponin I in a patient and may also be used in the diagnosis of, for example, a myocardial infarction or acute coronary syndrome.
    Type: Grant
    Filed: February 24, 2009
    Date of Patent: October 4, 2011
    Assignee: Abbott Laboratories
    Inventors: Susan E. Brophy, Bailin Tu, Joan D. Tyner, Lowell J. Tyner, legal representative, Dagang Huang, Robert N. Ziemann
  • Patent number: 8030027
    Abstract: The present invention is a method for enhancing recombinant antibody production by co-expressing in a host cell a recombinant antibody and ERp23 protein, which facilitates oxidative folding and stability of the recombinant antibody thereby enhancing production.
    Type: Grant
    Filed: April 15, 2009
    Date of Patent: October 4, 2011
    Assignee: St. Jude Children's Research Hospital
    Inventors: Yuichiro Shimizu, Linda M. Hendershot
  • Publication number: 20110236930
    Abstract: The present invention features a chemoselective ligation reaction that can be carried out under physiological conditions. In general, the invention involves condensation of a specifically engineered phosphine, which can provide for formation of an amide bond between the two reactive partners resulting in a final product comprising a phosphine moiety, or which can be engineered to comprise a cleavable linker so that a substituent of the phosphine is transferred to the azide, releasing an oxidized phosphine byproduct and producing a native amide bond in the final product. The selectivity of the reaction and its compatibility with aqueous environments provides for its application in vivo (e.g., on the cell surface or intracellularly) and in vitro (e.g., synthesis of peptides and other polymers, production of modified (e.g., labeled) amino acids).
    Type: Application
    Filed: March 8, 2011
    Publication date: September 29, 2011
    Inventors: Eliana Saxon, Carolyn Ruth Bertozzi
  • Patent number: 8026092
    Abstract: The present invention provides replication competent polynucleotides that include a coding sequence encoding a hepatitis C virus polyprotein having adaptive mutations. The invention also includes methods for malting replication competent polynucleotides, identifying a compound that inhibits replication of a replication competent polynucleotide, selecting a replication competent polynucleotide, and detecting a replication competent polynucleotide.
    Type: Grant
    Filed: December 1, 2004
    Date of Patent: September 27, 2011
    Assignee: Board of Regents, the University of Texas System
    Inventors: Stanley M. Lemon, MinKyung Yi
  • Patent number: 8026351
    Abstract: Nucleic acids encoding various monocyte-derived proteins and related compositions, including purified proteins and specific antibodies are described. Methods of using such composition are also provided.
    Type: Grant
    Filed: June 10, 2009
    Date of Patent: September 27, 2011
    Assignee: Schering Corporation
    Inventors: Elizabeth Bates, Nathalie Fournier, Lionel Chalus, Pierre Garrone
  • Patent number: 8013140
    Abstract: It is intended to provide a promoter for inducing expression selectively and strongly in an immunocompetent cell and/or a blood cell such as a lymphocyte. In the invention, the object was achieved by finding that HHV6 MIE promoter, HHV7 MIE promoter and HHV7 U95 promoter unexpectedly induce a specific expression in an immunocompetent cell and/or a blood cell such as a T lymphocyte. By utilizing the promoters, a selective delivery of a DNA vaccine or the like can be realized.
    Type: Grant
    Filed: August 21, 2008
    Date of Patent: September 6, 2011
    Assignee: The Resarch Foundation for Microbial Diseases of Osaka Universtiy
    Inventors: Masaya Takemoto, Yasuko Mori, Koichi Yamanishi, Isao Fuke, Yasuyuki Gomi, Michiaki Takahashi
  • Patent number: 8012931
    Abstract: Modified FGF-21 polypeptides and uses thereof are provided.
    Type: Grant
    Filed: March 19, 2008
    Date of Patent: September 6, 2011
    Assignee: Ambrx, Inc.
    Inventors: Thomas P. Cujec, Roberto Mariani, Anna-Maria A. Hays Putnam, William M. Keefe, Nick Knudsen, Lillian Ho, Jason Pinkstaff, Vadim Kraynov
  • Patent number: 8013139
    Abstract: It is intended to provide a promoter for inducing expression selectively and strongly in an immunocompetent cell and/or a blood cell such as a lymphocyte. In the invention, the object was achieved by finding that HHV6 MIE promoter, HHV7 MIE promoter and HHV7 U95 promoter unexpectedly induce a specific expression in an immunocompetent cell and/or a blood cell such as a T lymphocyte. By utilizing the promoters, a selective delivery of a DNA vaccine or the like can be realized.
    Type: Grant
    Filed: August 21, 2008
    Date of Patent: September 6, 2011
    Assignee: The Research Foundation for Microbial Diseases of Osaka University
    Inventors: Masaya Takemoto, Yasuko Mori, Koichi Yamanishi, Isao Fuke, Yasuyuki Gomi, Michiaki Takahashi
  • Publication number: 20110212489
    Abstract: A proteolysate of a seed material derived from a plant species of the Asteraceae family, such as sunflower, has improved properties as a constituent of a culture medium for culturing eukaryotic, in particular animal cells. The seed material is defatted and is hydrolysed to a degree of 10-50% and subsequently separated from insolubles. The cells are particularly cultured for producing desired protein products.
    Type: Application
    Filed: August 4, 2008
    Publication date: September 1, 2011
    Inventors: Mireille Maria Gadellaa, Edward Allen Hunter
  • Patent number: 8008043
    Abstract: Provided are processes for culturing cells derived from embryonic retinoblast cells immortalized by adenovirus E1 sequences, such as PER.C6® cells, to improve product yields from such cells. Feed strategies for such cells and cultures with very high cell densities are provided, resulting in high yields of products, such as recombinant antibodies.
    Type: Grant
    Filed: July 26, 2010
    Date of Patent: August 30, 2011
    Assignee: Crucell Holland B.V.
    Inventor: Christopher A. Yallop
  • Publication number: 20110207171
    Abstract: The present invention generally relates to methods of functionalizing proteins, particularly antibodies, at oligosaccharide linkages, methods of humanizing antibodies by modifying glycosylation, as well as to novel antibodies linked to modified oligosaccharides. The invention further relates to kits that may be used to produce the antibodies of the invention.
    Type: Application
    Filed: January 14, 2011
    Publication date: August 25, 2011
    Applicant: LIFE TECHNOLOGIES CORPORATION
    Inventors: Brian Agnew, Schuyler B. CORRY, Kyle R. GEE
  • Publication number: 20110207174
    Abstract: Disclosed is a culture medium for culturing an animal cell, which is characterized by containing a peptide comprising, as a constituent unit, an amino acid residue selected from the amino acid group consisting of serine, tyrosine and cysteine. The culture medium is suitable for the high level production of a protein by an animal cell.
    Type: Application
    Filed: October 27, 2009
    Publication date: August 25, 2011
    Inventors: Satoshi Katayama, Shouhei Kishishita, Kunihiko Kodaira, Makoto Sadamitsu, Yoshinori Takagi, Hiroki Matsuda
  • Patent number: 8003607
    Abstract: An HGF precursor protein variant, in which a peptide structure comprises a sequence including a peptide chain X inserted between an ? chain of HGF or a polypeptide where 1 to 20 amino-acid residues from the C-terminus of the ? chain are deleted, and a ? chain of HGF or a polypeptide where 1 to 20 amino-acid residues from the N-terminus of the ? chain are deleted; wherein (i) the peptide chain X has an amino-acid sequence of at least two residues, (ii) the peptide chain X can be cleaved by a protease reaction or a chemical reaction, and (iii) a protein obtained by cleaving at least one site of the peptide chain X has HGF action.
    Type: Grant
    Filed: March 30, 2007
    Date of Patent: August 23, 2011
    Assignees: Kringle Pharma Inc., Osaka University
    Inventors: Toshikazu Nakamura, Kunio Matsumoto, Kazuhiro Fukuta, Kiichi Adachi, Daichika Hayata
  • Patent number: 7998705
    Abstract: The present invention generally relates to novel processes for protein purification in high salt solutions such as cell culture broth by increasing the dynamic binding capacity of a resin with the addition of polyethylene glycol.
    Type: Grant
    Filed: November 12, 2002
    Date of Patent: August 16, 2011
    Assignee: FUJIFILM Diosynth Biotechnologies U.S.A., Inc
    Inventors: Min Wan, Mark David Chavez, Jeffrey Lee Schrimsher
  • Patent number: 7993920
    Abstract: Disclosed herein are methods of producing pancreatic hormone-expressing cells by first differentiating pluripotent cells in cell culture so as to produce endodermal cells, the endodermal cells being competent to further differentiate into hormone-expressing cells capable of secreting at least one pancreatic hormone in response to a physiological signal, and then, transplanting the cultured endodermal cells into an organism, such as an organism in need of an endocrine cell therapy.
    Type: Grant
    Filed: April 12, 2010
    Date of Patent: August 9, 2011
    Assignee: Viacyte, Inc.
    Inventors: Laura Martinson, Evert Kroon, Kevin D'Amour, Emmanuel Edward Baetge
  • Patent number: 7989204
    Abstract: Disclosed herein are methods for producing liver precursor cells as well as hepatocyte cells form pluripotent and/or multipotent cells. Also disclosed herein are methods of enriching isolating and/or purifying liver precursor cells and/or hepatocyte cells. Further disclosed are compositions comprising cell cultures and cell populations that are enriched for liver precursor cells or hepatocyte cells.
    Type: Grant
    Filed: April 27, 2007
    Date of Patent: August 2, 2011
    Assignee: Viacyte, Inc.
    Inventors: Kevin D'Amour, Emmanuel E. Baetge
  • Patent number: 7972813
    Abstract: The present invention is directed to a chimp sodium channel alpha subunit and methods and compositions for making and using the same.
    Type: Grant
    Filed: September 29, 2006
    Date of Patent: July 5, 2011
    Assignee: Vertex Pharmaceuticals Incorporated
    Inventors: Kenneth McCormack, Christopher Raj Dinesh
  • Patent number: 7968313
    Abstract: This invention is in the general field of recombinant expression of polypeptides in animal cell culture. More particularly, the invention concerns improved selection in cells of recombinantly engineered vectors designed to express polypeptides.
    Type: Grant
    Filed: November 6, 2009
    Date of Patent: June 28, 2011
    Assignee: Amgen Inc.
    Inventors: Jeffrey T. McGrew, Allison A. Bianchi
  • Patent number: 7968315
    Abstract: The expression vectors and methods using an E. coli expression system for the large scale production of IL-29 are described. The vectors utilize the IL-29 coding sequence with specific changes in nucleotides in order to optimize codons and mRNA secondary structure for translation in E. coli. Also included are methods of producing, purifying and pegylating an IL-29 polypeptide.
    Type: Grant
    Filed: February 5, 2010
    Date of Patent: June 28, 2011
    Assignee: ZymoGenetics, Inc.
    Inventors: Bruce L. Zamost, Robert M. Dedinsky
  • Publication number: 20110151100
    Abstract: The proposed patent describes a commercially viable process for production of biosurfactants and biopolymers by employing environmentally safe utilization of waste oil after recycling or during the early stage recycling. The process described eliminates use of strong solvents or acids during the process as has been suggested by other inventors. The entire process is achieved without addition of any nutrients during fermentation and there will not be any waste produced for disposal. The end products are natural and biodegradable and have many useful industrial and commercial applications. The invention is one of the many application of patented biodispersion technology (U.S. Pat. No. 6,267,888). The invention describes production of biosurfactant from both marine water and fresh water as a source for fermentation. Three byproducts are produced during the process namely 1. Oil for recycling/blending, 2. Process water for production of biosurfactants and 3.
    Type: Application
    Filed: December 19, 2009
    Publication date: June 23, 2011
    Inventor: Satyanarayana Ganti
  • Patent number: 7964399
    Abstract: The present invention relates to the use of ligands for the FLK-1 receptor for the modulation of angiogenesis and vasculogenesis. The invention s based, in part, on the demonstration that Flk-1 tyrosine kinase receptor expression is associated with endothelial cells and the identification of vascular endothelial growth factor (VEGF) as the high affinity ligand of Flk-1. These results indicate a major role for Flk-1 in the signaling system during vasculogenesis and angiogenesis. Engineering of host cells that express Flk-1 and the uses of expressed Flk-1 to evaluate and screen for drugs and analogs of VEGF involved in Flk-1 modulation by either agonist or antagonist activities is described. The invention also relates to the use of FLK-1 ligands, including VEGF agonists and antagonists, in the treatment of disorders, including cancer, by modulating vasculogenesis and angiogenesis.
    Type: Grant
    Filed: March 15, 2004
    Date of Patent: June 21, 2011
    Assignees: Max-Planck-Gesellschaft zur Forderung der Wissenschaften e.V., Yissum Research, Development Company of the Hebrew University of Jerusalem
    Inventors: Axel Ullrich, Werner Risau, Birgit Millauer, Aviv Gazit, Alex Levitzki
  • Patent number: 7964395
    Abstract: The present invention provides an attenuated virus, which is derived from Modified Vaccinia Ankara virus and characterized by the loss of its capability to reproductively replicate in human cell lines. It further describes recombinant viruses derived from this virus and the use of the virus, or its recombinants, as a medicament or vaccine. A method is provided for inducing an immune response in individuals who may be immune-compromised, receiving antiviral therapy, or have a pre-existing immunity to the vaccine virus. In addition, a method is provided for the administration of a therapeutically effective amount of the virus, or its recombinants, in a vaccinia virus prime/vaccinia virus boost inoculation regimen. The present invention relates to a method of virus amplification in primary cells which are cultivated in a serum free medium. Viruses produced by this method are advantageously free of any infectious agents comprised in animal sera.
    Type: Grant
    Filed: August 28, 2008
    Date of Patent: June 21, 2011
    Assignee: Bavarian Nordic A/S
    Inventors: Paul Chaplin, Paul Howley, Christine Meisinger-Henschel, Ingmar Rathe, Eva Felder, Karl Heller
  • Patent number: 7964398
    Abstract: The present invention provides an attenuated virus, which is derived from Modified Vaccinia Ankara virus and characterized by the loss of its capability to reproductively replicate in human cell lines. It further describes recombinant viruses derived from this virus and the use of the virus, or its recombinants, as a medicament or vaccine. A method is provided for inducing an immune response in individuals who may be immune-compromised, receiving antiviral therapy, or have a pre-existing immunity to the vaccine virus. In addition, a method is provided for the administration of a therapeutically effective amount of the virus, or its recombinants, in a vaccinia virus prime/vaccinia virus boost innoculation regimen. The present invention relates to a method of virus amplification in primary cells which are cultivated in a serum free medium. Viruses produced by this method are advantageously free of any infectious agents comprised in animal sera.
    Type: Grant
    Filed: July 14, 2010
    Date of Patent: June 21, 2011
    Assignee: Bavarian Nordic A/S
    Inventors: Paul Chaplin, Paul Howley, Christine Meisinger-Henschel, Ingmar Rathe, Eva Felder, Karl Heller
  • Patent number: 7964374
    Abstract: The present invention relates to novel insertion sites useful for the integration of exogenous sequences into the Modified Vaccinia Ankara (MVA) virus genome. The present invention further provides plasmid vectors to insert exogenous DNA into the genome of MVA. Furthermore, the present invention provides recombinant MVA comprising an exogenous DNA sequence inserted into said new insertion site as medicine or vaccine.
    Type: Grant
    Filed: May 19, 2009
    Date of Patent: June 21, 2011
    Assignee: Bavarian Nordic A/S
    Inventors: Paul Howley, Sonja Leyrer
  • Patent number: 7964397
    Abstract: The present invention relates to a method for the cultivation of primary cells. The primary cells are cultivated in a serum free medium comprising a factor selected from the group consisting of growth factors and attachment factors. The method for the cultivation of primary cells may be one step in a method for the amplification of viruses, such as poxviruses. According to this latter method the primary cells are cultivated in a serum free medium comprising a factor selected from the group consisting of growth factors and attachment factors. The cells are then infected with the virus and the infected cells are cultivated in serum free medium until progeny virus is produced.
    Type: Grant
    Filed: October 1, 2008
    Date of Patent: June 21, 2011
    Assignee: Bavarian Nordic A/S
    Inventors: Ingmar Rathe, Eva Felder, Karl Heller
  • Patent number: 7960534
    Abstract: Isolated and/or purified polypeptides and nucleic acid sequences encoding polypeptides from Alicyclobacillus acidocaldarius are provided. Further provided are methods for transporting sugars across cell membranes using isolated and/or purified polypeptides and nucleic acid sequences from Alicyclobacillus acidocaldarius.
    Type: Grant
    Filed: February 26, 2009
    Date of Patent: June 14, 2011
    Assignee: Battelle Energy Alliance, LLC
    Inventors: David N. Thompson, William A. Apel, Vicki S. Thompson, David W. Reed, Jeffrey A. Lacey
  • Publication number: 20110137012
    Abstract: Methods of culturing cells capable of producing desired proteins to obtain the proteins by use of a medium from which biological components are excluded as much as possible are provided. Specifically, a culture method characterized by culturing while maintaining a specific amino acid in a culture solution at a high concentration, and a cell culture fed-batch medium for use in the method are provided.
    Type: Application
    Filed: April 25, 2008
    Publication date: June 9, 2011
    Inventors: Satoshi Katayama, Shouhei Kishishita, Kunihiko Kodaira, Makoto Sadamitsu, Yoshinori Takagi, Hiroki Matsuda
  • Patent number: 7955792
    Abstract: The present invention relates to a diluent for a Norovirus or Sapovirus specimen, the diluent containing an alkaline buffer of pH 9.0 to 10.0, and to a method for detecting a Norovirus or a Sapovirus through use of the diluent. According to the present invention, a Norovirus or a Sapovirus can be detected in a Norovirus- or Sapovirus-containing specimen such as stool, vomit, body fluid, blood, body tissue, or food, in a convenient manner without use of a special machine such as a centrifuge, with an improved detection sensitivity, and with complete elimination of non-specific factors.
    Type: Grant
    Filed: March 31, 2004
    Date of Patent: June 7, 2011
    Assignee: Denka Seiken Co., Ltd.
    Inventors: Kunio Kamata, Daisuke Kato
  • Publication number: 20110130544
    Abstract: The present invention relates to antibodies with decreased deamidation profiles, and methods for producing antibodies with decreased deamidation profiles.
    Type: Application
    Filed: March 25, 2008
    Publication date: June 2, 2011
    Applicant: MEDIMMUNE, LLC
    Inventors: Kripa Ram, Raghavan Venkat
  • Patent number: 7947470
    Abstract: Novel genes significantly homologous to organic cation transporters OCT1 and OCT2 have been successfully isolated by screening a fetal gene library by random sequencing. Proteins encoded by these genes function as transporters of various organic cations.
    Type: Grant
    Filed: January 21, 2004
    Date of Patent: May 24, 2011
    Assignee: Chugai Seiyaku Kabushiki Kaisha
    Inventors: Jun-Ichi Nezu, Asuka Oku
  • Patent number: 7947286
    Abstract: Filovirus subunit protein immunogens are produced using a recombinant expression system and combined with one or more adjuvants in immunogenic formulations. The subunit proteins include GP95, GP-FL, VP40, VP24, and NP derived from Ebola Virus and Marburg Virus. Adjuvants include saponins, emulsions, alum, and dipeptidyl peptidase inhibitors. The disclosed immunogenic formulations are effective in inducing strong antibody responses directed against individual Filovirus proteins and intact Filovirus particles as well as stimulating cell-mediated immune responses to the Filoviruses.
    Type: Grant
    Filed: October 5, 2006
    Date of Patent: May 24, 2011
    Assignee: PanThera Biopharma LLC
    Inventors: Axel Thomas Lehrer, David Edward Clements, Tom Humphreys
  • Patent number: 7947474
    Abstract: Novel polypeptides, polynucleotides encoding the polypeptides, and related compositions and methods are disclosed for zyctor17, a novel cytokine receptor. The polypeptides may be used within methods for detecting ligands that stimulate the proliferation and/or development of hematopoietic, lymphoid and myeloid cells in vitro and in vivo. Ligand-binding receptor polypeptides can also be used to block ligand activity in vitro and in vivo. The polynucleotides encoding zyctor17, are located on chromosome 5, and can be used to identify a region of the genome associated with human disease states. The present invention also includes methods for producing the protein, uses therefor and antibodies thereto.
    Type: Grant
    Filed: October 20, 2006
    Date of Patent: May 24, 2011
    Assignee: ZymoGenetics, Inc.
    Inventors: Cindy A. Sprecher, Scott R. Presnell, Zeren Gao, Theodore E. Whitmore, Joseph L. Kuijper, Mark F. Maurer
  • Patent number: 7943736
    Abstract: The present invention provides insecticidal polypeptides related to Bacillus Cry2 polypeptides. Nucleic acids encoding the polypeptides of the invention are also provided. Methods for using the polypeptides and nucleic acids of the invention to enhance resistance of plants to insect predation are encompassed.
    Type: Grant
    Filed: April 28, 2010
    Date of Patent: May 17, 2011
    Assignee: Pioneer Hi-Bred International, Inc.
    Inventors: Ericka Bermudez, Robin Emig, Kevin McBride, Takashi Yamamoto
  • Patent number: 7943735
    Abstract: The present invention provides insecticidal polypeptides related to Bacillus Cry2 polypeptides. Nucleic acids encoding the polypeptides of the invention are also provided. Methods for using the polypeptides and nucleic acids of the invention to enhance resistance of plants to insect predation are encompassed.
    Type: Grant
    Filed: April 27, 2010
    Date of Patent: May 17, 2011
    Assignee: Pioneer Hi-Bred International, Inc.
    Inventors: Ericka Bermudez, Robin Emig, Kevin McBride, Takashi Yamamoto
  • Patent number: 7943737
    Abstract: The present invention provides insecticidal polypeptides related to Bacillus Cry2 polypeptides. Nucleic acids encoding the polypeptides of the invention are also provided. Methods for using the polypeptides and nucleic acids of the invention to enhance resistance of plants to insect predation are encompassed.
    Type: Grant
    Filed: April 28, 2010
    Date of Patent: May 17, 2011
    Assignee: Pioneer Hi-Bred International, Inc.
    Inventors: Ericka Bermudez, Robin Emig, Kevin McBride, Takashi Yamamoto
  • Patent number: 7943734
    Abstract: The present invention provides insecticidal polypeptides related to Bacillus Cry2 polypeptides. Nucleic acids encoding the polypeptides of the invention are also provided. Methods for using the polypeptides and nucleic acids of the invention to enhance resistance of plants to insect predation are encompassed.
    Type: Grant
    Filed: April 27, 2010
    Date of Patent: May 17, 2011
    Assignee: Pioneer International, Inc.
    Inventors: Ericka Bermudez, Robin Emig, Kevin McBride, Takashi Yamamoto
  • Patent number: 7939077
    Abstract: The present invention relates to an antibody against FGF-8, particularly a humanized antibody against FGF-8 and the antibody fragment thereof, a DNA sequence encoding the above antibody or the antibody fragment, a vector comprising the DNA sequence and a host cell transformed by the vector, a production process of the above antibody or the antibody fragment using the host cell, and a therapeutic agent and a diagnostic agent for cancer using the antibody or the antibody fragment.
    Type: Grant
    Filed: June 28, 2002
    Date of Patent: May 10, 2011
    Assignee: Kyowa Hakko Kirin Co., Ltd.
    Inventors: Kenya Shitara, Kazuyasu Nakamura, Maiko Hirota, Naoki Shimada
  • Publication number: 20110097749
    Abstract: The present invention provides a novel method for producing biologically functional hepcidin in Pichia pastoris. The invention further provides novel tagged hepcidin, antibodies and their uses in therapy and immunoassays.
    Type: Application
    Filed: August 22, 2008
    Publication date: April 28, 2011
    Applicants: HELLENIC PASTEUR INSTITUTE
    Inventors: Avgi Mamalaki, Martha Marinou, Vasiliki Koliaraki
  • Patent number: 7932358
    Abstract: Novel cell surface molecules recognized by monoclonal antibodies against a cell surface molecule of lymphocytic cells that play an important role in autoimmune diseases and allergic diseases have been isolated, identified, and analyzed for their functions. The cell surface molecules are expressed specifically in thymocytes, lymphocytes activated by ConA-stimulation, and peripheral blood lymphocytes, and induce cell adhesion. Antibodies against the cell surface molecules significantly ameliorate pathological conditions of autoimmune diseases and allergic diseases.
    Type: Grant
    Filed: November 12, 2007
    Date of Patent: April 26, 2011
    Assignee: Japan Tobacco Inc.
    Inventors: Takuya Tamatani, Katsunari Tezuka
  • Patent number: 7932369
    Abstract: An isolated nucleotide sequence or fragment thereof encoding the porcine intrinsic factor, wherein the porcine intrinsic factor comprises an amino acid sequence having at least 85% amino acid sequence identity to an amino acid sequence selected from the group consisting of SEQ ID NO: 3, SEQ ID NO: 6, and SEQ ID NO: 9. The invention also encompasses an isolated nucleic acid sequence or fragment thereof comprising, or complementary to, a nucleotide sequence having at least 85% nucleotide sequence identity to a nucleotide sequence selected from the group consisting of SEQ ID NO: 1, SEQ ID NO: 4, and SEQ ID NO: 7. The porcine intrinsic factor can be use is an assay to determine the quantity of vitamin B12 in a biological sample.
    Type: Grant
    Filed: July 8, 2009
    Date of Patent: April 26, 2011
    Inventors: Ramani S. Wonderling, John F. Uher
  • Patent number: 7923221
    Abstract: The invention relates to processes for producing an immunoglobulin or an immunologically functional immunoglobulin fragment containing at least the variable domains of the immunoglobulin heavy and light chains. The processes can use one or more vectors which produce both the heavy and light chains or fragments thereof in a single cell. The invention also relates to the vectors used to produce the immunoglobulin or fragment, and to cells transformed with the vectors.
    Type: Grant
    Filed: April 13, 1995
    Date of Patent: April 12, 2011
    Assignees: Genentech, Inc, City of Hope
    Inventors: Shmuel Cabilly, Herbert L. Heyneker, William E. Holmes, Arthur D. Riggs, Ronald B. Wetzel
  • Patent number: 7919597
    Abstract: A cell extract for cell-free protein synthesis is produced by removing substances, which bind to an affinity support to be used in purification or interaction analysis, from a cell extract having protein synthetic activity. Then, a target protein is synthesized by using the cell extract for cell-free protein synthesis. The synthesized target protein can be purified by using the affinity support and used in interaction analysis.
    Type: Grant
    Filed: July 30, 2010
    Date of Patent: April 5, 2011
    Assignee: Cellfree Sciences Co., Ltd.
    Inventors: Yoshiko Yoshiyama, Hirohisa Koga
  • Patent number: 7919257
    Abstract: The present invention provides combinations of specific binding proteins, such as immunoglobulins, that are designed to be true combinations, essentially all components of the combination being functional and compatible with each other. The invention further provides a method for producing a composition comprising at least two different proteinaceous molecules comprising paired variable regions, the at least two proteinaceous molecules having different binding specificities, comprising paired variable regions, at least two proteinaceous molecules having different binding specificities, comprising contacting at least three different variable regions under conditions allowing for pairing of variable regions and harvesting essentially all proteinaceous molecules having binding specificities resulting from the pairing.
    Type: Grant
    Filed: November 30, 2005
    Date of Patent: April 5, 2011
    Assignee: Merus Biopharmaceuticals, B.V.i.o.
    Inventors: Hendricus Renerus Jacobus Mattheus Hoogenboom, Ton Logtenberg
  • Patent number: 7914792
    Abstract: The present invention relates to compositions and methods for raising antibodies generally comprising 1) providing highly immunogenic vesicles bearing at least one target antigen and 2) immunizing animals with the said antigen-bearing vesicles to induce antigen-specific antibody responses. The invention also relates to methods of screening antibody repertoires comprising 1) providing vesicles bearing at least one target antigen and one marker and 2) isolating antibody-producing cells or particles with defined antigen specificity using the said antigen- and marker-bearing vesicles. Antibodies with defined antigen specificity can then be prepared from isolated antibody-producing cells using known methods of the art. This invention can be used in experimental, research, therapeutic, prophylactic or diagnostic areas.
    Type: Grant
    Filed: February 13, 2004
    Date of Patent: March 29, 2011
    Assignee: Exothera L.L.C.
    Inventors: Alain Delcayre, Jean-Bernard Le Pecq
  • Patent number: 7910362
    Abstract: A reporter vector which can evaluate the ability of a drug to induce CYP1A2 or both of CYP1A1 and CYP1A2 and a method for evaluation of the ability of a drug to induce CYP1A2 or both of CYP1A1 and CYP1A2 by using the reporter vector. A reporter system which can evaluate the ability of a drug capable of inducing CYP1A2 or both of CYP1A1 and CYP1A2 is completed by constructing a reporter vector having a reporter gene linked to the 3? end of a region between CYP1A1 and CYP1A2 or a reporter vector having different reporter genes linked to the both ends of the region, respectively, so as to sandwich the region, and a reporter vector having a deletion mutation in the region, and confirming that the expression of a reporter molecule is increased by the drug capable of inducing CYP1A2 or both of CYP1A1 and CYP1A2 in the reporter system using the reporter vector.
    Type: Grant
    Filed: July 12, 2006
    Date of Patent: March 22, 2011
    Assignees: Eisai R&D Management Co., Ltd., Tohoku University
    Inventors: Rika Ueda, Kazutomi Kusano, Yasushi Yamazoe, Kiyoshi Nagata
  • Publication number: 20110053224
    Abstract: The invention describes a novel composition of matter obtained from the leaves of green plants, which is useful in promoting the growth of beneficial microorganisms. Specifically, that the invention describes a hydrolysate prepared from plant leaf biomass (leaf biomass hydrolysate or ‘LBH’) which dramatically stimulates the growth of beneficial microorganisms. Use of LBH as a fermentation substrate can also stimulate rapid production of organic acids and other organic compounds. LBH can be used as a substrate to promote the fermentation-based production of biobased industrial chemicals or biofuels, LBH can be utilized as a prebiotic to promote the growth of beneficial probiotic organisms, hi addition, LBH may also be useful in stimulating the fermentation-based production of other products, examples of which include preservatives, antibiotics, antigens, vaccines, amino acids, vitamins, recombinant proteins, bioremediation treatments, and immobilized enzymes.
    Type: Application
    Filed: January 26, 2009
    Publication date: March 3, 2011
    Inventors: Yangming Martin Lo, Irene N.N. Yossa, Neil A. Belson